Cosmos Pharmaceutical Limited | CAPTOCOS®
Cosmos Limited is one of the leading manufacturers of pharmaceutical products in Kenya and East Africa. Through our specialized Human Health and Animal Health.
Cosmos Limited,top pharmaceutical,top pharma,best pharma,best pharmaceutical,leading pharma,leading pharmaceutical,pharma,cosmos pharmaceutical,cosmos,cosmos Kenya,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,company,companies,manufacturer in Kenya,manufacturers in Kenya,Delvin Mugo,Mugo Delvin,manufacturers in east Africa,manufacturers in Africa ,Cosmos, cosmos pharmaceuticals,pharmaceuticals, pharmaceutical,pharmaceutical company in Kenya,pharmaceuticals companies in Kenya,pharmaceutical company in Nairobi, pharmaceuticals companies in Nairobi,pharmaceuticals companies Nairobi,Kenya pharmaceuticals companies,Nairobi pharmaceuticals,top pharma,best pharma,leading pharma,pharma,top pharmaceutical,best pharmaceutical,leading pharmaceutical,medicine,veterinary,animal health,human health,Kenya pharmaceutical,best medicine,Kenya best medicine,Nairobi manufacturer,best manufacturer,profitable company in Kenya,company,companies,manufacturer in Kenya,manufacturers in Kenya,manufacturers in east Africa,manufacturers in Africa,pharmacy in Kenya,pharmaceutical supplies in Kenya,pharmacies in Kenya,chemists in Kenya,chemist in Kenya,pharmaceutical companies in Kenya,leading pharmaceutical in Kenya, best pharmaceutical in Nairobi,best pharmaceutical in Kenya, pharmaceuticals companies Nairobi, pharmaceuticals companies Kenya, pharmaceuticals products distributor in Nairobi, pharmaceuticals products distributor in Kenya,Kenya Quality Healthcare Products, Quality Healthcare Products,A renown Pharmaceutical company in Kenya,A renown Pharmaceutical
page-template,page-template-full_width,page-template-full_width-php,page,page-id-17902,ajax_updown_fade,page_not_loaded,,side_area_uncovered_from_content,overlapping_content,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-13.6,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.5,vc_responsive



Captopril is an angiotensin-converting enzyme (ACE) inhibitor which reduces peripheral resistance and lowers blood pressure. ACE inhibitors are antihypertensive drugs that act as vasodilators and reduce peripheral resistance. The pharmacological actions of ACE inhibitors are thought to be primarily due to the inhibition of the renin-angiotensin-aldosterone system. ACE inhibitors produce a reduction in both preload and afterload in patients with heart failure. They also reduce left ventricular remodelling. Normally, renal blood flow is increased without a change in glomerular filtration rate.

About 60 to 75% of a dose of Captopril is absorbed from the gastro-intestinal tract and peak plasma concentrations are achieved within about an hour. Absorption has been reported to be reduced in the presence of food. Captopril is about 30% bound to plasma proteins. It crosses the placenta and is found in breast milk at about 1% of maternal blood concentrations. It is largely excreted in the urine, 40 to 50% as unchanged drug, the rest as disulfide and other metabolites. The elimination half-life has been reported to be 2 to 3 hours but this is increased in renal failure. Captopril is removed by haemodialysis.


Captocos® tablets are used in the management of hypertension, in heart failure, following myocardial infarction and in diabetic nephropathy.



Hypertension: The initial dose is 12.5mg twice daily by mouth, increased gradually at intervals of 2 to 4 weeks according to the response. The usual maintenance dose is 25 to 50mg twice daily and should not exceed 50mg three times daily.
Heart failure: An initial dose of 6.25 to 12.5mg. The usual maintenance dose is 25mg two or three times daily, doses should not exceed 50mg three times daily.
Myocardial infarction: It may be started 3 days after Myocardial infarction in an initial dose of 6.25mg by mouth, increased over several weeks to 150mg daily in divided doses.
Diabetic nephropathy (microalbuminuria greater than 30mg per day) in type 1 diabetics: 75 to 100mg daily in divided doses by mouth. In patients with severe renal impairment (creatinine clearance less than 30mL per minute) an initial dose of 12.5mg twice daily.


Captocos® should not be used in patients with aortic stenosis or outflow tract obstruction, and  in patients with renovascular disease. Patients with existing renal disease or  taking high doses should be monitored regularly for proteinuria. Regular white blood cell counts may be necessary in patients with collagen vascular disorders, such as systemic lupus erythematosus and scleroderma, or in patients receiving immunosuppressive therapy, especially when they also have impaired renal function.

Adverse Effects:

They include: Hypotension, dizziness, fatigue, headache, gastro-intestinal disturbances, taste disturbances, persistent dry cough and other upper respiratory tract symptoms, skin rashes (including erythema multiforme and toxic epidermal necrolysis), angioedema, hypersensitivity reactions, renal impairment, hyperkalaemia, hyponatraemia and blood disorders.
Use in Pregnancy:
Captocos® should not be used during pregnancy.


Excessive hypotension may occur when ACE inhibitors are used concurrently with diuretics, other antihypertensives, or other agents, including alcohol, that may lower blood pressure. Potassium-sparing diuretics and potassium supplements should generally be stopped before initiating ACE inhibitors in patients with heart failure.


Store in a dry place below 25°C.  Protect from light.  Keep all medicines out of the reach of children.

Prescription Only Medicine (POM)
®Regd. TM               Ref. No.: INS098/01.06

  • CAPTOCOS®25 Tablets

    PresentationLight blue, circular biconvex tablet embossed 'COSMOS' on one side and a breakline on the other side. Each tablet contains: Captopril BP 25mg. Pack size - 30's (3x10's)